Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marta Biondi"'
Autor:
Antonio Maria Alviano, Marta Biondi, Erica Grassenis, Andrea Biondi, Marta Serafini, Sarah Tettamanti
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Although adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells has achieved unprecedented response rates in patients with certain hematological malignancies, this therapeutic modality is still far from fulfilling its remarkable pote
Externí odkaz:
https://doaj.org/article/760e2cdc4feb44e598668ee57efb0640
Autor:
Andrea Biondi, Gianpietro Dotti, Alice Pievani, Marta Biondi, Sarah Tettamanti, Marta Serafini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Abstract
Externí odkaz:
https://doaj.org/article/202b57b4527d46eabfa5cf891656ed44
Autor:
Silvia Arcangeli, Laura Falcone, Barbara Camisa, Federica De Girardi, Marta Biondi, Fabio Giglio, Fabio Ciceri, Chiara Bonini, Attilio Bondanza, Monica Casucci
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Chimeric antigen receptor (CAR) T cell expansion and persistence emerged as key efficacy determinants in cancer patients. These features are typical of early-memory T cells, which can be enriched with specific manufacturing procedures, providing sign
Externí odkaz:
https://doaj.org/article/566b2b6edfac40ce85ed4f163b8a2092
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 5, p 1513 (2020)
Despite extensive research and development of new treatments, acute myeloid leukemia (AML)-backbone therapy has remained essentially unchanged over the last decades and is frequently associated with poor outcomes. Eradicating the leukemic stem cells
Externí odkaz:
https://doaj.org/article/124ad954a9a64d499e2e2c1d387afcf0
Autor:
Marta Biondi, Sarah Tettamanti, Stefania Galimberti, Beatrice Cerina, Chiara Tomasoni, Rocco Piazza, Samantha Donsante, Simone Bido, Vincenzo Maria Perriello, Vania Broccoli, Andrea Doni, Francesco Dazzi, Alberto Mantovani, Gianpietro Dotti, Andrea Biondi, Alice Pievani, Marta Serafini
Publikováno v:
Blood.
Acute myeloid leukemia (AML) is a hematological malignancy derived from neoplastic myeloid progenitor cells characterized by abnormal clonal proliferation and differentiation. Although novel therapeutic strategies have recently been introduced, the p
Autor:
Marta Biondi, Stefania Galimberti, Beatrice Cerina, Chiara Tomasoni, Gianpietro Dotti, Sarah Tettamanti, Andrea Biondi, Alice Pievani, Marta Serafini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e9b644f8e2fb1bab10f9bc3371af7bf
https://hdl.handle.net/10281/401661
https://hdl.handle.net/10281/401661
Autor:
Beatrice Cerina, Sarah Tettamanti, Gianpietro Dotti, Alice Pievani, Marta Serafini, Chiara Tomasoni, Marta Biondi, Andrea Biondi
Publikováno v:
Blood. 138:2791-2791
Chimeric Antigen Receptor (CAR) T cell therapy is a promising treatment for acute myeloid leukemia (AML), but a limited efficacy was reported from ongoing clinical trials. The capacity of engineered T cells to infiltrate into the bone marrow (BM) nic